Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Synthesis And Evaluation Of A Technetium-99m Labeled Cytotoxic Bombesin Peptide Conjugate For Targeting Bombesin Receptor-expressing Tumors.

S. Okarvi, I. Al Jammaz
Published 2010 · Medicine, Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Conjugation of the cytotoxic drugs to receptor-binding peptides is an attractive approach for the targeted delivery of cytotoxic peptide conjugates to tumor cells. In an attempt to develop an efficient peptide-based radiopharmaceutical for targeting bombesin (BN) receptor-expressing tumors (i.e., breast and prostate), we have prepared by solid-phase peptide synthesis, a novel BN analog derived from the universal sequence of BN and conjugated to a widely characterized antineoplastic agent, methotrexate (MTX). MTX-BN, after radiolabeling with (99m)Tc via stannous-tartrate exchange, showed a good stability against cysteine and histidine transchelation as well as a high in vitro metabolic stability in human plasma. In vitro cell-binding and internalization on MDA-MB-231, MCF-7, T47-D breast cancer and PC-3 prostate cancer cell lines demonstrated high affinity and specificity of (99m)Tc-MTX-BN towards both human breast and prostate cancer cells (binding affinities in nanomolar range). In addition, the radioconjugate displayed a significant internalization (values ranged between 19-35%) into the tumor cells. In vivo biodistribution and clearance kinetics in Balb/c mice are characterized by an efficient clearance from the blood and excretion mainly through the renal-urinary pathway with some elimination via the hepatobiliary system. In vivo tumor uptake in nude mice bearing MDA-MB-231 cells was 2.70+/-0.44% ID/g at 1 h, whereas in nude mice with human epidermoid KB cells the accumulation in the tumor was found to be 1.48+/-0.31% ID/g at 1 h post injection. The tumor uptake was always higher than in the blood and muscle, with good tumor retention and good tumor-to-blood and tumor-to-muscle ratios. The accumulation/retention in the major organs (i.e., lungs, stomach, liver, intestines, etc.) was low to moderate (<6% ID/g) in both healthy and tumor-bearing mice. However, the uptake/retention in the kidneys was rather high (up to 11.05+/-1.80% ID/g), which is of a concern, particularly for radionuclide therapy. This initial study towards the development of a novel cytotoxic BN conjugate suggest that the combination of favorable in vitro and in vivo properties may render (99m)Tc-MTX-BN a potential candidate for the targeted imaging and eventually for radionuclide therapy (when labeled with an appropriate radionuclide) of BN receptor-positive tumors and deserves further evaluation.
This paper references
Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes.
T. Pradhan (1998)
In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties.
J. J. Parry (2007)
Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
J. Garrison (2008)
Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors
Hanwen Zhang (2004)
Transport of methotrexate into PC-3 human prostate cancer cells.
D. Horne (2001)
Imaging tumor folate receptors using 111In-DTPA-methotrexate.
S. Ilgan (1998)
Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the european amphibiansBombina andAlytes
A. Anastasi (2005)
Characterization of Receptors for α-Melanocyte-stimulating Hormone on Human Melanoma Cells
W. Siegrist (1989)
Karnofsky memorial lecture. Ode to methotrexate.
J. Bertino (1993)
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.
A. Schally (2003)
Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells
H. Reile (1994)
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
W. Breeman (2002)
Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments.
A. Fleischmann (2005)
Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors*
S. Mantey (1997)
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
E. Rolleman (2002)
Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent.
S. Okarvi (2004)
Role of the membrane-associated folate binding protein (folate receptor) in methotrexate transport by human KB cells.
J. C. Deutsch (1989)
Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
G. Halmos (1995)
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
T. Hoffman (2003)
Guide for the Care and Use of Laboratory Animals
Division on Earth (1996)
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
L. E. Lantry (2006)
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
A. Nagy (1997)
Candidates for peptide receptor radiotherapy today and in the future.
J. Reubi (2005)
Characterization, in some human breast cancer cell lines, of gastrin‐releasing peptide‐like receptors which are absent in normal breast epithelial cells
S. Giacchetti (1990)
Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases
A. Fleischmann (2000)
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
C. J. Smith (2005)
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
A. Schally (1999)
Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies.
P. Lundquist (2005)
Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
S. Okarvi (2008)
Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.
A. Nagy (1993)
True radiotracers: Cu-64 targeting vectors based upon bombesin peptide.
T. Hoffman (2009)
NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
K. Eisenwiener (2002)
Development and Validation of a Liquid Chromatographic Method for the Analysis of Positron Emission Tomography Radiopharmaceuticals with Ru(bpy)32+-KMnO4 Chemiluminescence Detection
R. Nakao (2007)
Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents.
S. Okarvi (2006)
Comparison of the stability of technetium-labeled peptides to challenge with cysteine.
M. Stalteri (1999)
Sensitive determination of specific radioactivity of positron emission tomography radiopharmaceuticals by radio high-performance liquid chromatography with fluorescence detection.
R. Nakao (2008)
Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
B. Faintuch (2008)
Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP).
Tomoo Nakagawa (2005)
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.
R. Cai (1994)
Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
Yishan Yang (2006)
Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14)
J. Reubi (2002)
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
M. Shipp (1991)

This paper is referenced by
SPECT/PET Imaging with Technetium, Gallium, Copper, and Other Metallic Radionuclides
R. Alberto (2013)
Peptide-MediatedTargetedDrugDelivery Sumit Majumdar and Teruna
J. Siahaan (2012)
Eutimio Gustavo (2011)
Inorganic nanoparticles in diagnosis and treatment of breast cancer
C. Núñez (2018)
Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI.
Atefeh Jafari (2015)
Breast cancer: early diagnosis and effective treatment by drug delivery tracing.
Mahdiyeh Shamsi (2017)
Development of a peptide-based bifunctional chelator conjugated to a cytotoxic drug for the treatment of melanotic melanoma.
Raghuvir H Gaonkar (2018)
Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor
K. De (2017)
99m Tc-(EDDA/tricine)-HYNIC-GnRH analogue as a potential imaging probe for diagnosis of prostate cancer.
Arezou Masteri Farahani (2020)
BBN conjugated GNPs: a new targeting contrast agent for imaging of breast cancer in radiology.
M. Salouti (2017)
Nanoparticulate targeted drug delivery using peptides and proteins
H. Santos (2012)
Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
S. Okarvi (2012)
A Multifunctional Radiotheranostic Agent for Dual Targeting of Breast Cancer Cells
F. Vultos (2017)
Peptide‐mediated targeted drug delivery
S. Majumdar (2012)
Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: implications for the rational design of new targeted drug therapies.
K. Varini (2019)
A study on drug delivery tracing with radiolabeled mesoporous hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells.
Mahdiyeh Shamsi (2018)
Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma.
S. Okarvi (2016)
Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
S. Dissanayake (2017)
Size and specificity of radiopharmaceuticals for sentinel lymph node detection
E. G. F. Núñez (2011)
A convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer
Subhani M. Okarvi (2019)
Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine
P. Halik (2020)
Breast cancer photothermal therapy based on gold nanorods targeted by covalently-coupled bombesin peptide.
Zahra Heidari (2015)
Synthesis, development and preclinical study of EDDA based 99mTc-5-fluorouracil for brain imaging
N. Ahmed (2016)
Dual-targeting conjugates designed to improve the efficacy of radiolabeled peptides.
Christiane A. Kluba (2012)
Methotrexate: a detailed review on drug delivery and clinical aspects
Zulfequar Ahamad Khan (2012)
Gold nanorods-bombesin conjugate as a potential targeted imaging agent for detection of breast cancer.
Zahra Heidari (2014)
Prostate cancer relevant antigens and enzymes for targeted drug delivery.
Ashutosh Barve (2014)
In vitro/in vivo assessment of the targeting ability of [99mTc] Tc-labeled an aptide specific to the extra domain B of fibronectin (APTEDB) for colorectal cancer
Leila Ranjbar (2020)
Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions
F. Shariati (2014)
Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas
S. Okarvi (2019)
Recent advances in improving tumor-targeted delivery of imaging nanoprobes.
Qianyi Zhang (2020)
Semantic Scholar Logo Some data provided by SemanticScholar